Osimertinib and Low-Dose Itraconazole Combination: Vigilance in Elderly Patients
@article{Khoudour2019OsimertinibAL, title={Osimertinib and Low-Dose Itraconazole Combination: Vigilance in Elderly Patients}, author={Nihel Khoudour and Annelise Martin and Marie Allard and M. Tiako Meyo and B. Blanchet}, journal={Annals of Pharmacotherapy}, year={2019}, volume={53}, pages={321 - 322} }
Figures and Topics from this paper
Figures
References
SHOWING 1-5 OF 5 REFERENCES
Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
- Chemistry, Medicine
- CPT: pharmacometrics & systems pharmacology
- 2018
- 21
Liquid chromatography‐tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non‐small cell lung cancer patients
- Chemistry, Medicine
- Journal of pharmaceutical and biomedical analysis
- 2018
- 16
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib
- Medicine
- British journal of clinical pharmacology
- 2018
- 20
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old
- Medicine
- Investigational New Drugs
- 2016
- 10
Proposal for a New Tool to Evaluate Drug Interaction Cases
- Medicine
- The Annals of pharmacotherapy
- 2007
- 449
- PDF